Abstract
Background Buprenorphine is a synthetic opioid frequently used in combination with naloxone for the treatment of opioid use disorder (OUD). Overall buprenorphine distribution has increased nationally; however, pronounced regional differences in this distribution have also been identified. The objective of this study was to analyze buprenorphine distribution by three-digit zip codes in Pennsylvania from 2010-2020.
Methods Data was extracted from the Drug Enforcement Administration’s Automated Reports and Consolidated Orders System (ARCOS) yearly to gather buprenorphine distribution, in grams per 3-digit zip code, from 2010-2020. After compiling this data, a percent change for each 3-digit zip code was calculated to analyze the change in distribution from 2010-2020. The total weight of buprenorphine distributed for the state of Pennsylvania over the last decade was calculated. The amount of buprenorphine distributed in grams per each 3-digit zip code was compared to their population densities to analyze if there was any association between population and buprenorphine distribution. Zip codes that were outside of a 95% confidence interval were considered significant (p < .05).
Results Pennsylvania pharmacies and hospitals dispensed 116.3 kg of buprenorphine in 2010. That number increased 217.3% to 369.0 kg in 2020. The 155-zip code (Somerset) experienced the largest increase (885%). In contrast the 190-zip (Philadelphia) experienced the smallest increase (79%). The 155 (Somerset), 169 (Wellsboro), and 177 (Williamsport) zip codes experienced significantly greater elevations relative to the state average.
Conclusion Our analysis uncovered that buprenorphine distribution in Pennsylvania from 2010-2020 rose 217%. With the increasing awareness of opioid addiction, and the large number of opioid prescriptions in the US, this increase was expected. The zip codes of 155, 169, 177 showed a statistically significant increase in buprenorphine distribution relative to the overall state average. No zip codes displayed a statistically significant decrease in buprenorphine distribution. Interestingly, some of the more densely populated areas in Pennsylvania were at or below the average state increase of 217% (Pittsburgh 150-152 – 228%; Philadelphia 190-191 – 79%; Harrisburg 170-171 – 202%). Furthermore, the statistically significant zip codes of 155, 169, and 177 were among the least densely populated areas of Pennsylvania. Further pharmacoepidemiological research is needed to continue to characterize, and ideally remediate, the pronounced regional variation in buprenorphine distribution.
Competing Interest Statement
BJP was part of an osteoarthritis research team from 2019 to 2021 supported by Pfizer and Eli Lilly. The other authors do not report any conflicts of interest.
Funding Statement
This study was supported by the Health Resources Services Administration (D34HP31025).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used ONLY openly available human data that were originally located at: https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
rrinaldi{at}som.geisinger.edu
sgrampp{at}som.geisinger.edu
kmccall{at}binghamton.edu
psy391{at}gmail.com
Data Availability
All data is available online at: https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html
https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html
